OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 5.9 EUR -4.07% Market Closed
Market Cap: 129.4m EUR

OSE Immunotherapeutics SA
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

OSE Immunotherapeutics SA
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
OSE Immunotherapeutics SA
PAR:OSE
Interest Income Expense
-€5.8m
CAGR 3-Years
-161%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Interest Income Expense
-€24.8m
CAGR 3-Years
-44%
CAGR 5-Years
-235%
CAGR 10-Years
-28%
Nanobiotix SA
PAR:NANO
Interest Income Expense
-€10.4m
CAGR 3-Years
N/A
CAGR 5-Years
-20%
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Interest Income Expense
-€2.6m
CAGR 3-Years
44%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Interest Income Expense
-€8.2m
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Interest Income Expense
-€3.4m
CAGR 3-Years
-68%
CAGR 5-Years
-32%
CAGR 10-Years
-29%

OSE Immunotherapeutics SA
Glance View

Market Cap
128.4m EUR
Industry
Biotechnology

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

OSE Intrinsic Value
7.94 EUR
Undervaluation 26%
Intrinsic Value
Price

See Also

What is OSE Immunotherapeutics SA's Interest Income Expense?
Interest Income Expense
-5.8m EUR

Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Interest Income Expense amounts to -5.8m EUR.

What is OSE Immunotherapeutics SA's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
-161%

The average annual Interest Income Expense growth rates for OSE Immunotherapeutics SA have been -161% over the past three years .

Back to Top